MolecularMD signs licensing agreement with Oregon Health & Science University

Gleevec a targeted tyrosine kinase inhibitor drug is said to be a highly effective front line therapy for the treatment of chronic mylogenous leukemia (CML). The drug blocks the unregulated enzyme activity of the fusion tyrosine kinase protein BCR-ABL. BCR-ABL stems from a chromosomal translocation forming the Philadelphia chromosome present in malignant bone marrow cells of CML patients.

While most CML patients exhibit excellent primary response to imatinib, a proportion of patients develop acquired secondary resistance via point mutations in the ABL kinase domain. These mutations can interfere with the binding of imatinib to the BCR-ABL protein and lead to disease progression.

Brian Druker, scientific founder of MolecularMD, said: “MolecularMD is well positioned to further develop methods for the detection of Gleevec resistant mutations and to support clinical, pharmaceutical, and diagnostic organizations dedicated to improving CML patient outcomes.”